NAS:ITCI (USA) Also Trade In: Germany
Intra-Cellular Therapies Inc $ 23.95 -0.91 (-3.66%)
Warning! GuruFocus has detected 5 Severe warning signs with ITCI. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for Intra-Cellular Therapies Inc () from 2013 to Oct 27 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Intra-Cellular Therapies stock (ITCI) PE ratio as of Oct 27 2020 is 0. More Details
Intra-Cellular Therapies PE Ratio (TTM) Historical Data
View and export this data going back to 2013. Start your Free Trial
Intra-Cellular Therapies PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:EDIT OTCPK:CYDY NAS:AKCA NAS:SGMO NYSE:RCUS NAS:RGNX NAS:CNST NAS:YMAB NAS:INVA NAS:AKBA OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Address 430 East 29th Street, New York, USA, 10016
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.